Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist
Choose a source to read (4)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Renal guidance: 2.4 Dosage Adjustment in Patients with Renal Impairment / 5.2 New Onset or Worsening Renal Impairment / 8.6 Renal Impairment
For the adult 300 mg TDF tablet, increase the interval when CrCl falls below 50 mL/min. The 50-80 mL/min group needs no renal adjustment. No regimen is established below 10 mL/min without HD or for children with renal impairment. Use the separate HD row and monitor renal toxicity.
Source revision: DailyMed SPL version 31, posted Feb 24, 2025 | Retrieved: 2026-11-07. Retrieval date is not the revision date.
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
Source scope / renal recommendation differences
Viread - product and source limitations
No regimen is established below 10 mL/min without HD or for children with renal impairment. Use the separate HD row and monitor renal toxicity.
How to use this: Apply only to the stated formulation, indication and renal population.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Important source distinctions
Tenofovir disoproxil fumarate 300 mg only, not tenofovir alafenamide or a fixed-dose combination.
The NIH addition is specifically tenofovir disoproxil fumarate (TDF). Do not apply it to tenofovir alafenamide (TAF) or a fixed-dose combination.
Locally stored source content
Original GlobalRPh protocol
Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/tenofovir/
Usual Dosing (Adults)
VIREAD for HIV-1 or chronic hepatitis B: 300 mg orally once daily, without regard to food. The source states the optimal HBV treatment duration is unknown.
CrCl above 50 mL/min: usual dose. 30-49: 300 mg every 48 hours. 10-29: 300 mg twice weekly. Below 10 without dialysis: no recommendation available. Exactly 50 is not explicitly assigned in the original text.
Renal guidance: 2.4 Dosage Adjustment in Patients with Renal Impairment / 5.2 New Onset or Worsening Renal Impairment / 8.6 Renal Impairment
For the adult 300 mg TDF tablet, increase the interval when CrCl falls below 50 mL/min. The 50-80 mL/min group needs no renal adjustment. No regimen is established below 10 mL/min without HD or for children with renal impairment. Use the separate HD row and monitor renal toxicity.
RDM74-viread-official-1 · Source locator: Renal guidance: 2.4 Dosage Adjustment in Patients with Renal Impairment / 5.2 New Onset or Worsening Renal Impairment / 8.6 Renal Impairment
Renal method: Use the renal measure explicitly present in the RX passage. Source date: Mirror revision not established in the reviewed passage. Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
NIH ClinicalInfo adult ARV panel · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method: CrCl mL/min; single-agent TDF only Source date: Revision date not stated in the reviewed page. Retrieved: 2026-09-05
Locally included source-specific summary. Regimen differences are not automatically resolved.
Dosing / renal protocol and limits
Single-agent TDF: usual 300 mg orally daily. CrCl 30-49: 300 mg every 48 hours; 10-29: 300 mg every 72-96 hours; <10 without HD: no recommendation. HD: 300 mg every 7 days after dialysis. Do not apply this to TAF or fixed combinations.
RDM30-099-tenofovir-1 · Source locator: NIH adult ARV table - tenofovir disoproxil fumarate; renal/dosing sections and stated qualifiers
Additional summaries stored on this page: 1 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.
